1. Home
  2. HUDI vs BCDA Comparison

HUDI vs BCDA Comparison

Compare HUDI & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Huadi International Group Co. Ltd.

HUDI

Huadi International Group Co. Ltd.

N/A

Current Price

$1.27

Market Cap

18.1M

Sector

Industrials

ML Signal

N/A

BCDA

BioCardia Inc.

N/A

Current Price

$1.29

Market Cap

14.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HUDI
BCDA
Founded
1998
N/A
Country
China
United States
Employees
N/A
N/A
Industry
Steel/Iron Ore
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.1M
14.5M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
HUDI
BCDA
Price
$1.27
$1.29
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$25.00
AVG Volume (30 Days)
46.2K
95.8K
Earning Date
02-02-2026
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$66,566,370.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.06
$1.00
52 Week High
$5.46
$3.20

Technical Indicators

Market Signals
Indicator
HUDI
BCDA
Relative Strength Index (RSI) 56.69 46.10
Support Level $1.24 $1.35
Resistance Level $1.35 $1.43
Average True Range (ATR) 0.08 0.07
MACD 0.01 -0.00
Stochastic Oscillator 80.49 37.50

Price Performance

Historical Comparison
HUDI
BCDA

About HUDI Huadi International Group Co. Ltd.

Huadi International Group Co Ltd is a manufacturer of industrial stainless steel seamless pipes and tubes products. Its products are used in the oil & gas transmission, chemistry engineering, food processing, medical devices, aeronautics and astronautics, boiler, irrigation works construction, automobile and naval architecture, paper mill and mechanical industries. Company generates revenue from Sales of steel piping products. Products are exported to the United States, Mexico, Thailand, Singapore, Argentina, Taiwan, India, the Philippines, UAE and Canada. Geographically, majority revenue is generated from China.

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Share on Social Networks: